What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025Blood

PyramIDH: A phase 3 study of ivosidenib monotherapy or azacitidine monotherapy in patients with mutant isocitrate dehydrogenase 1 myelodysplastic syndromes who have not received prior hypomethylating agent therapy

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial compared azacitidine with ivosidenib in patients with lower-risk myelodysplastic syndromes, suggesting improved treatment options.

Ivosidenib monotherapy led to higher remission rates, enhancing outcomes in lower-risk patients with myelodysplastic syndromes.
Complete remission and partial remission rates were notably higher than the standard drug therapy azacitidine.
Multicenter, phase 3, open-label study compared ivosidenib and azacitidine in treatment-naive patients with MDS.
The trial highlights the need for better treatment options, especially for patients prone to acute myeloid leukemia.

Platzbecker et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial compared azacitidine with ivosidenib in patients with lower-risk myelodysplastic syndromes, suggesting improved treatment options.

Ivosidenib monotherapy led to higher remission rates, enhancing outcomes in lower-risk patients with myelodysplastic syndromes.
Complete remission and partial remission rates were notably higher than the standard drug therapy azacitidine.
Multicenter, phase 3, open-label study compared ivosidenib and azacitidine in treatment-naive patients with MDS.
The trial highlights the need for better treatment options, especially for patients prone to acute myeloid leukemia.

Platzbecker et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark